| 引用本文: | 刘艳华,王明权,朱伟英,卢燕君,王文佳.CDK4/6抑制剂在消化道肿瘤中的临床研究进展[J].中国现代应用药学,2021,38(18):2333-2336. |
| LIU Yanhua,WANG Mingquan,ZHU Weiying,LU Yanjun,WANG Wenjia.Progress of Clinical Study of CDK4/6 Inhibitors in Gastrointestinal Tumors[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(18):2333-2336. |
|
| 摘要: |
| 细胞周期蛋白依赖性激酶（cyclin dependent kinase，CDK）4/6抑制剂在阻止肿瘤生长、疾病发展和提高存活率方面显示出显著的效果，是目前抗肿瘤药物研发的热点，临床上已用于乳腺癌和非小细胞肺癌的治疗。CDK4/6在消化道肿瘤中有扩增和过度表达，CDK4/6抑制剂在消化道肿瘤中已陆续展开临床试验，本文就近期CDK4/6抑制剂在食管癌、胃癌、结直肠癌中的临床试验情况进行综述。 |
| 关键词: CDK4/6抑制剂 临床试验 食管癌 胃癌 结直肠癌 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.18.021 |
| 分类号:R735 |
| 基金项目: |
|
| Progress of Clinical Study of CDK4/6 Inhibitors in Gastrointestinal Tumors |
|
LIU Yanhua1, WANG Mingquan2, ZHU Weiying1, LU Yanjun1, WANG Wenjia1
|
|
1.Hangzhou Simbos Pharm Co., Ltd., Hangzhou 311121, China;2.Hangzhou Kewan New Material Technology Co., Ltd., Lin'an 311305, China
|
| Abstract: |
| Cyclin dependent kinase(CDK) 4/6 inhibitors have shown significant effects in preventing tumor growth, disease development, and improving survival rates. They are currently a hot spot in the research and development of anti-cancer drugs and have been clinically applied in the treatment of breast cancer and non-small cell lung cancer. CDK4/6 is amplified and overexpressed in gastrointestinal tumors. CDK4/6 inhibitors have been studied in gastrointestinal tumors. This article reviews the recent clinical trials of CDK4/6 inhibitors in esophageal cancer, gastric cancer, and colorectal cancer. |
| Key words: CDK4/6 inhibitors clinical trial esophageal cancer gastric cancer colorectal cancer |
